Keytruda, a cancer-immunotherapy medicine, ranks among the most lucrative drugs ever sold. Since its launch in 2014 it has raked in over $130bn in sales for Merck, its American maker, including $29.5bn last year. In September last year an experimental drug did what none had done before. In late-stage trials for non-small-cell lung cancer, it nearly doubled the time patients lived without the disease worsening—to 11.1 months, compared with 5.8 months for Keytruda.....
From The Economist
one perspective, which I share, is Americans subsidize a lot of the world, including medications.
And keep one eye on south Korea....
any chance you could copy and paste article… it’s behind a paywall for me.
Thanks!
If you can read Greek, sure. It was reprinted in translation by a Greek newspaper of the financial sector press aka Ναυτεμπορικη (Naftemboriki).
I could put it through google translate! so yes please!!
Enjoy reading
naftemporiki.gr/finance/wor...
Thank you!!
Great article… very interesting and full of promise. Hopefully will bring in a raft of cheaper, more effective treatments quickly.
Adaptive Therapy as it applies to the treatment of cancer: Part One - A Personal Perspective 
? Any progress in the history of "War on Cancer"
AMG 509 (Xaluritamig) updates about the clinical trial
Developments in the nanoparticle world and how to determine and predict chemo benefits in MHSPCAdvaxis--a Company with 2 Prostate Cancer Vaccine Candidates
